Caredx Stock Price, News & Analysis

CareDx (NASDAQ:CDNA), a precision medicine company focused on transplant healthcare solutions, has appointed Nathan Smith as its new Chief Financial Officer. Smith brings over 14 years of experience in molecular diagnostics, including senior finance roles at Myriad Genetics and CFO positions at Blackrock Neurotech and WIN Brands.

The appointment comes as current CFO Abhishek Jain announces his retirement, though he will continue supporting the company in a consulting capacity to ensure a smooth transition. CEO John Hanna emphasized Smith's operational excellence and experience in scaling diagnostics companies efficiently as key factors for the company's next growth phase.

CareDx (NASDAQ:CDNA) reported Q2 2025 financial results with mixed performance. The company achieved adjusted revenue of $90.5 million, up 14% year-over-year, while testing services volume grew 13% to 49,500 tests. AlloSure Kidney testing volumes showed strong growth of nearly 20% year-over-year.

The company reported a GAAP net loss of $8.6 million ($0.16 per share) but achieved non-GAAP net income of $5.6 million ($0.10 per share). CareDx maintains a strong balance sheet with $186 million in cash after completing a $50 million share repurchase. The company narrowed its full-year 2025 revenue guidance to $367-373 million and maintained adjusted EBITDA guidance of $29-33 million.

Notable business achievements include the publication of the KOAR manuscript, launch of AlloSure Plus AI-driven diagnostic platform, and successful EPIC environment installation.

CareDx (NASDAQ: CDNA) has published its landmark Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation, demonstrating the clinical utility of its AlloSure® donor-derived cell-free DNA (dd-cfDNA) test in kidney transplant surveillance.

The extensive study, involving 1,743 patients across 56 U.S. transplant centers and 18,584 AlloSure tests, revealed that elevated AlloSure was associated with a 6-fold increase in rejection detection in surveillance biopsies and a 4-fold increase in for-cause biopsies. The test can detect rejection up to four months before antibody-mediated rejection (ABMR) and one month before T-cell mediated rejection (TCMR), positioning it as a powerful early detection tool in kidney transplantation.

CareDx (NASDAQ:CDNA) announced significant advancements in AI-powered transplant diagnostics at the 2025 World Transplant Congress, featuring over 40 abstracts and 16 oral presentations. The company unveiled AlloSure® Plus, an AI-driven diagnostic platform integrated with EPIC Aura, validated through 2,700+ renal transplant biopsies by the Paris Transplant Group.

Key research findings include: an 8.166-fold increased risk of graft loss in kidney transplant recipients with elevated dd-cfDNA, successful monitoring of hard-to-place kidney transplants, and nearly doubled risk of complications in heart transplant recipients with elevated biomarkers. The company will host a symposium on August 4, 2025, focusing on precision molecular intelligence in transplant management.

CareDx (NASDAQ:CDNA), a company specializing in transplant healthcare solutions, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close.

The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone using the numbers 1-800-274-8461 (domestic) or 1-203-518-9814 (international) with Conference ID: CareDx, or through the webcast available on the company's investor relations website.

CareDx (NASDAQ:CDNA) announced a proposed draft Local Coverage Determination (LCD) that maintains coverage for surveillance testing in solid organ transplant rejection detection. The draft LCD, open for comments until August 31, 2025, continues to provide coverage for kidney, heart, and lung transplant surveillance testing without requiring protocol biopsy.

The policy introduces a bundled payment concept for surveillance testing. CareDx will provide additional information during its earnings call on August 6, 2025. The company's CEO, John W. Hanna, emphasized that this draft policy reinforces coverage for surveillance testing and supports their position on improving transplant patient outcomes.

CareDx has completed a $50 million share repurchase program, buying back approximately 5% of its outstanding shares. The company reported strong performance with seven consecutive quarters of testing services growth and Q1 revenue of $84.7 million, up 18% year-over-year. CareDx maintains a strong financial position with $231 million in cash and equivalents and no debt. The Board has authorized a new $50 million share repurchase program for the next 24 months. CEO John W. Hanna expressed confidence in the company's growth trajectory, targeting $500 million in revenue and 20% adjusted EBITA by 2027.

CareDx (NASDAQ: CDNA), a precision medicine company specializing in transplant healthcare solutions, has announced its participation in three major upcoming investor conferences in May and June 2025:

- Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis on May 28
- Jefferies Global Healthcare Conference 2025 in New York with a presentation on June 5 at 10:30 a.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference in Miami featuring a fireside chat on June 9 at 3:20 p.m. ET

Webcasts for the June 5th and June 9th events will be available through CareDx's Investor Relations website.

CareDx reported strong Q1 2025 financial results with total revenue reaching $84.7 million, an 18% year-over-year increase. The company achieved its seventh consecutive quarter of growth in testing services, with volume rising to 47,100 tests.

Key highlights include:

• Testing services revenue: $61.9 million (+15% YoY)
• Patient and Digital Solutions revenue: $12.0 million (+24% YoY)
• Product revenue: $10.8 million (+26% YoY)

While reporting a GAAP net loss of $10.4 million, the company showed significant improvement with non-GAAP net income of $5.4 million and positive adjusted EBITDA of $4.6 million. CareDx maintains a strong financial position with $231 million in cash and no debt. The company reaffirmed its 2025 revenue guidance of $365-375 million and introduced expanded indications for AlloSure Testing Services.